STOCK MARKET BSE NSE

Emergency use authorization request filed with FDA for paediatric use of Bharat Biotech's Covaxin

The submission is based on the results of a Phase 2/3 paediatric clinical trial conducted by Bharat Biotech in India with 526 children 2-18 years of age.

Published: 05th November 2021 09:13 PM  |   Last Updated: 05th November 2021 09:13 PM   |  A+A-

The first consignment of Bharat Biotech’s Covaxin being dispatched from Hyderabad.

For representational purposes

By PTI

HYDERABAD: Ocugen Inc., Bharat Biotech's partner for USA and Canada for COVID-19 vaccine Covaxin on Friday, November 5, 2021, said it has submitted a request to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the jab for paediatric use.

The submission is based on results of a Phase 2/3 paediatric clinical trial conducted by Bharat Biotech in India with 526 children 2-18 years of age, which bridged immunogenicity data to a large, Phase 3 safety and efficacy clinical trial in nearly 25,800 adults in India, Ocugen said in a regulatory filing.

"Filing for Emergency Use Authorization in the U.S. for paediatric use is a significant step toward our hope to make our vaccine candidate available here and help combat the COVID-19 pandemic," Shankar Musunuri, Chairman of the Board, Chief Executive Officer and Co-Founder of Ocugen said.

Some research suggests that people are seeking more choices when selecting a vaccine, especially for their children.

Having a new type of vaccine available will enable people to discuss with their child's physician the best approach for them to lower their child's risk of contracting COVID-19, he further said.

"The inactivated virus platform has been used for decades in vaccines for the paediatric population and, if authorized, we hope to offer another vaccine option to protect children as young as two years," he added.

A Phase 2/3, open-label, multi-center study was conducted in India from May 2021 to July 2021 to evaluate the safety, reactogenicity and immunogenicity of the whole-virion inactivated Vaccine in healthy volunteers in the 2-18 age group.

Covaxin was evaluated in three age groups: 2-6 years, 6-12 years and 12-18 years.

All participants received two doses of the vaccine 28 days apart, it said.

Covaxin was recently awarded Emergency Use Listing by the World Health Organization.



Comments

Disclaimer : We respect your thoughts and views! But we need to be judicious while moderating your comments. All the comments will be moderated by the newindianexpress.com editorial. Abstain from posting comments that are obscene, defamatory or inflammatory, and do not indulge in personal attacks. Try to avoid outside hyperlinks inside the comment. Help us delete comments that do not follow these guidelines.

The views expressed in comments published on newindianexpress.com are those of the comment writers alone. They do not represent the views or opinions of newindianexpress.com or its staff, nor do they represent the views or opinions of The New Indian Express Group, or any entity of, or affiliated with, The New Indian Express Group. newindianexpress.com reserves the right to take any or all comments down at any time.

edexworks
flipboard facebook twitter whatsapp